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Molecular Cloning of Human Dectin-2
To the Editor:
Murine dectin-2 is a type II C-type lectin receptor and highly
associated with dendritic cells (DC), including Langerhans
cells (LC) (Ariizumi et al, 2000; Bonkobara et al, 2001). It
bears no signaling motif but is highly homologous (61%
identity) to murine DC immunoactivating receptor (DCAR),
which acts as an activating receptor through association
with Fc receptor g chain (Kanazawa et al, 2003). Its function
including the activating capacity, however, has been mostly
unknown. Furthermore, it has remained to be clarified
whether its human counterpart is really present or not. In
this report, we successfully isolated the human orthologue
of murine dectin-2 and investigated its mRNA expression
profile.
Alignment of a BAC clone of human chromosome 12
(GenBank accession number AC092865) with exons 3 and 4
of murine DCAR provided us the putatively orthologous
exons of human clone with appropriate exon–intron
boundaries. The full-length cDNA of this human clone was
obtained with rapid amplifications of cDNA ends using the
cDNA library of human spleen. The contiguous contig is
1613 base pairs in length excluding the poly A tail and
contains a putative open reading frame of 627 base pairs
(Fig 1a). Hydrophobicity profile of the deduced amino acids
(Fig 1b) demonstrates the presence of a hydrophobic signal
anchor of 27 amino acids (underlined in Fig 1a), indicating
that this molecule is a type II transmembrane protein.
Although its short cytoplasmic portion contains no tyrosine
residue associated with a signaling motif, its extracellular
portion contains six consensus cysteines (circled in Fig 1a)
forming the carbohydrate recognition domain (CRD). The
domain structure of this molecule is shown in Fig 1b.
Nucleotide sequence alignment with the human chromo-
some 12 genomic contig (GenBank accession number
NT_024397) enabled us to demonstrate the genomic
structure of this gene with appropriate exon-intron bound-
aries. This gene is composed of six exons representing
functional domains as shown in Fig 1c. These domain and
genomic structures are almost the same as those of murine
dectin-2 (Ariizumi et al, 2000). Genes of this human clone
and some related C-type lectins, including DC immuno-
receptor (DCIR; Bates et al, 1999), C-type lectin-like receptor
6 (CLEC6; GenBank accession number AF411850) and
macrophage-inducible C-type lectin (Mincle; Matsumoto
et al, 1999), are localized on a short region of the human
chromosome 12 genomic contig (Fig 1d), which is reported-
ly located on the telomeric end of the natural killer gene
complex (Hofer et al, 2001). CLEC6 is considered as the
human counterpart of murine macrophage-restricted
C-type lectin (MCL; Balch et al, 1998), because of their
high sequence homology (60% identity, data not shown).
Comparing the order of these genes with that of the murine
counterparts on chromosome 6, the position of this novel
human clone is considered exactly syntenic to that of
murine dectin-2 (Kanazawa et al, 2003).
Overall amino acid sequence of this human clone shows
68% identity with that of murine dectin-2, 52% with murine
DCAR and 54% with human BDCA-2 (Fig 1e). Although the
number of its whole amino acids is the same as that of both
murine DCAR and dectin-2, the result of alignment clearly
revealed that this human clone represents the putative
counterpart of murine dectin-2, rather than DCAR. Posi-
tively charged arginine residue in the transmembrane
domain (shown by a closed circle in Fig 1e), which can
partly explain the binding capacity of DCAR with Fc
receptor g chain (Kanazawa et al, 2003), is conserved in
this human clone and murine dectin-2 (lysine in BDCA-2).
The EPN motif in the CRD (shown by plus signs in Fig 1e),
which may be involved in the binding capacity of mannose-
type carbohydrate (Weis et al, 1998), is also conserved in
this human clone and murine dectin-2 as well as BDCA-2.
Collectively, this newly identified human clone has been
defined as the human orthologue of murine dectin-2.
Although BDCA-2 was proposed to be the human counter-
part of murine dectin-2 (Dzionek et al, 2001), isolated human
dectin-2 is similar but absolutely different from BDCA-2.
Considering that the genes of Ly-49 molecules are clustered
in the natural killer gene complex of only the murine genome
and turn to pseudogenes in human genome (Yokoyama,
1998), presence of distinct human dectin-2 indicates that
this molecule have a role in the human immune system.
Furthermore, expression profile of human dectin-2 was
examined with RT-PCR. Among normal human tissues,
expression of dectin-2 transcript was detected strongly in
the lung and weakly in the spleen, lymph nodes, peripheral
blood leukocytes, but not observed in the skin (Fig 2). In
mouse, dectin-2 mRNA expression was observed in the
spleen, thymus (Ariizumi et al, 2000), and lung (Fernandes
et al, 1999), but not in whole skin (Ariizumi et al, 2000).
Although the expression profile of human dectin-2 is similar
to that of the murine counterpart, its expression level in the
lung is surprisingly high (Fig 2). It should be further defined
what kind of cells in the lung are responsible for this strong
expression. Among fractionated peripheral blood cells,
human dectin-2 expression was quite strongly observed
in purified monocytes and weakly in B cells as well as
mononuclear cells (MNC), but not in CD4 and CD8 T cells.
After ex vivo activation, its expression was reduced in MNC
Abbreviations: CRD, carbohydrate recognition domain; DC, den-
dritic cells; DCAR, DC immunoactivating receptor; LC, Langerhans
cells; MNC, mononuclear cells; moDC, monocyte-derived DC
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Figure 1
Structures of the human dectin-2 cDNA, protein and gene. (a) Nucleotide and predicted amino acid sequences of human dectin-2 cDNA are
shown. This nucleotide sequence has been submitted to GenBank under accession number AY321309. The in-flame stop codon upstream of the
start codon is surrounded by an open square. The potential transmembrane domain is underlined and the six cysteine residues which are involved in
formation of the CRD are circled. The putative poly A additional signal is double underlined. (b) Hydrophobicity profile and the domain structure of
human dectin-2 protein are shown. GeneWorks software was used for calculation of the hydrophobicity. Numbers of amino acids (aa) represent the
junctions of sequential domains. The following abbreviations are used: CYT, cytoplasmic portion; TM, transmembrane domain; UTR, untranslated
region. (c) Numbers of nucleotides and deduced amino acids of all the exons and introns of human dectin-2 gene are shown. (d) Schematic view of
the genes of human dectin-2 and related C-type lectins (BDCA-2, DCIR, CLEC6, Mincle) on a short region of human chromosome 12 is shown. Each
gene is shown as a box and the distance of sequential genes is indicated by the number of nucleotides (kb: kilobases). (e) Deduced amino acid
sequence of human dectin-2 was aligned with that of its murine counterpart, human BDCA-2 and murine DCAR using MacVector software. Identical
and homologous residues are shaded dark and light, respectively. The potential transmembrane domain is underlined and the conserved positively-
charged residue is indicated by a closed circle. The cysteine residue which may be involved in dimer formation is indicated by a closed square and
the six conserved cysteine residues in the CRD are shown by asterisks. The EPN motif, which may be involved in the specific recognition of
mannose-type sugar, is shown by plus signs.
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and B cells, whereas interestingly, CD4 T cells turned to
produce dectin-2 (Fig 2). Although murine dectin-2 mRNA is
reportedly expressed in several hematopoietic cells, such
as B cell hybridoma cells (Ariizumi et al, 2000), precursor
and mature macrophages and mature neutrophils (Fer-
nandes et al, 1999), its expression was not recognized in
concanavalin A-stimulated T cells (Fernandes et al, 1999).
Among in vitro generated DC, human dectin-2 expression
was most strongly observed in immature LC-type DC and
very weakly in immature monocyte-derived DC (moDC).
After maturation, its expression was upregulated in moDC,
but reduced in LC-type DC (Fig 2). Exclusively strong
expression of human dectin-2 in immature LC-type DC is
quite consistent with the results of the promoter analysis of
its murine counterpart (Bonkobara et al, 2001). Although the
precise expression of human dectin-2 in vivo should be
further defined, our data suggest its role in activated CD4 T
cells as well as in antigen presenting cells, such as
monocytes and immature LC.
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Figure 2
Expression profile of human dectin-2 mRNA. RT-PCR was performed using specific primer pairs of human dectin-2 and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) on various human tissues and cell populations. Multiple tissue cDNA panels including Human MTC Panel I,
Human Immune System MTC Panel I and Human Blood Fractions MTC Panel were purchased from BD Biosciences Clontech. The other cDNA
samples were prepared manually from the normal human skin specimen and in vitro generated DC. For generation of immature LC-type DC or
moDC, non-adherent fraction of peripheral blood MNC were cultured in the presence of recombinant human granulocyte/macrophage colony-
stimulating factor and interleukin-4 with or without transforming growth factor b1 for 7 days, respectively. For generation of LC-type DC, interleukin-4
was added only in the first 2 days. To induce maturation, tumor necrosis factor a, interleukin-6, interleukin-1b and prostaglandin E2 were added into
the culture during the last 24 h. The primer pairs used for amplification of human dectin-2 were as follows; 50-CTG GGC AAC ATC TTT AGG GAG
AGA GG-30 (forward primer) and 50-GAA TGG AAC AAA GAG AGG AAG GGT GC-30 (reverse primer). Amplification of 34 cycles or 38 cycles was
performed for dectin-2, whereas 30 cycles for GAPDH. Amplified cDNA fragments were separated with 2% agarose gel electrophoresis.
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